Skip to main content

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG

NEW YORK, NY / ACCESSWIRE / November 19, 2015 / Pomerantz LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) ("AMAG" or the "Company"). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether AMAG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

November 18, 2015, AMAG announced that the Company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its application seeking approval for a single-dose vial of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in certain at-risk patients. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form.

On this adverse news, AMAG shares have fallen as much as $2.34, or 8.05%, on intraday trading on November 19, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.